<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3611393C-B14F-4035-B03B-9F07C2EAAD6F"><gtr:id>3611393C-B14F-4035-B03B-9F07C2EAAD6F</gtr:id><gtr:firstName>Gillian</gtr:firstName><gtr:surname>Bates</gtr:surname><gtr:orcidId>0000-0002-4041-6305</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7ADD968D-1D63-4687-B530-A7EC95C89DDF"><gtr:id>7ADD968D-1D63-4687-B530-A7EC95C89DDF</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Joanna</gtr:otherNames><gtr:surname>Tabrizi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL02053X%2F1"><gtr:id>0EA06AE7-0053-4B6E-BEA6-DEC9B0F3DCF0</gtr:id><gtr:title>Targeting the innate immune system in Huntington's disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L02053X/1</gtr:grantReference><gtr:abstractText>Huntington's disease (HD) is a fatal, inherited neurological condition. The earliest symptoms are often subtle problems with mood or cognition, followed by a lack of coordination and an unsteady gait. As the disease progresses, jerky body movements become more apparent, along with a decline in mental abilities and behavioural and psychiatric problems. Affected individuals also suffer progressive weight loss and muscle wasting. The disease typically progresses over several decades until death. There are a few effective treatments for some of the symptoms, but there is no cure that will halt or slow progression of the disease. The inherited nature of HD means that the children of affected individuals have a 50% chance of developing the disease themselves.
 
The disease is caused by a mutation in a single gene that encodes for a protein called huntingtin (HTT). The only difference between the mutated and normal versions of the gene is an increase in the number of repeats of the DNA sequence CAG close to its beginning. This causes an increase in the number of glutamines (an amino acid, the building blocks of proteins) in the HTT protein. This causes the HTT protein to behave in an aberrant fashion in the cells in which it's made.

HD is primarily thought of as disease of the brain, but the HTT protein (both the mutant and normal forms) is expressed in all the cells of the body. It is becoming increasingly recognised that there are significant changes outside of the brain in HD, including in muscle, heart, fat and, of interest here, the immune system. In fact, people carrying the HD gene show signs of increased inflammation, as shown by elevated levels of certain molecules in their blood. Beyond the urgent need for new therapies, one advantage of studying HD is that genetic testing can establish with 100% accuracy whether an individual carries the mutant gene or not, enabling us to study the disease before an individual develops any symptoms. In doing this, we have discovered that the increased inflammation in HD is observed many years before symptom onset. This suggests that inflammation might have long-term effects that are important in the development of the disease. 

We have also discovered that inflammation in HD is probably due to the aberrant behaviour of a particular group of immune cells, called monocytes and macrophages. These cells are hyper-responsive to immune stimulation and produce excessive levels of the inflammatory molecules detected in the blood of HD patients. It is becoming clear that the immune system causes changes in the brain and other tissues. Hence, it is conceivable that elevated inflammation in HD patients might be contributing to some of the changes in the brain and/or other tissues that cause the symptoms of the disease to worsen. There are already safe treatments available that will reduce inflammation in humans, but this strategy has not yet been tried in HD. 

Our aims are to determine whether inflammation really does contribute to HD progression and if so, whether we can use specific therapeutic agents to lower the inflammation to help treat the disease. We also want to discover the exact means by which the mutant HTT protein causes monocytes and macrophages to behave aberrantly, which may help identify alternative targets for developing treatments for HD.

To achieve these aims, we will undertake a range of experiments in cells from HD patients and in mouse models. We will determine exactly which genes are altered in HD monocytes and macrophages, and will attempt to discover how mutant HTT causes these changes to occur. We will treat HD mice with various agents that are expected to increase or decrease their levels of inflammation, including drugs that reduce inflammation and are already used for this purpose to treat other diseases. We hope that any positive results from these studies will lead to clinical trials in HD patients.</gtr:abstractText><gtr:technicalSummary>Huntington's disease (HD) is a fatal, inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene, leading to an expanded poly-glutamine tract in the HTT protein. Considerable evidence suggests that HD is associated with increased systemic inflammation that may contribute to progression of the disease. We have shown previously that myeloid cells from HD patients are hyper-responsive to stimulation and that this is due to the intrinsic expression of the mutant HTT protein in these cells.

Our hypothesis is that mHTT primes myeloid cell hyper-reactivity to immune stimulation and that the resultant low-level systemic inflammation contributes to HD progression. We aim to determine the mechanisms by which mHTT affects myeloid cells isolated from the blood of HD patients as compared to those from non-HD individuals, by means of full-transcriptome sequencing and methods to monitor transcription factor activation and binding. 

We also aim to establish the extent to which components of the peripheral innate immune system contribute to HD and to determine whether systemic inflammation can be targeted to modify disease progression. We will specifically target cells and pathways by genetic and/or pharmacological means in ways that might ameliorate aspects of disease, allowing us to dissect the contribution of specific cell populations, signalling pathways and molecules to HD progression. We hope this will form the basis of further work seeking therapeutic intervention that targets in peripheral innate immune system and systemic inflammation in HD.

Understanding the contribution that systemic inflammation makes to pathogenesis is essential in determining whether targeting it might be a viable therapeutic strategy in HD. A complete mechanistic understanding of these events may identify targets that lead to the development of novel therapies.</gtr:technicalSummary><gtr:potentialImpactText>The potential beneficiaries of our research include Huntington's disease patients and families, scientists and clinicians working on HD and/or neuroinflammation, as well as biotechnology and pharmaceutical companies with research and development and/or commercial interests in these areas. 

For researchers, an improved understanding of neuroinflammatory events will aid all researchers with an interest in the pathogenic basis of HD. It will also have important implications for the potential development a new therapeutic strategy in HD. To that end, if results are positive, we expect to receive the active support of the CHDI Foundation (whose letter of support is enclosed), a not-for-profit research organisation that works with scientists internationally to discover therapies that slow the progression of HD. The discovery of such therapies will be of considerable commercial interest to companies working in this area.

For patients, we hope the work will form the basis of developing treatments for those who have developed or are likely to develop the disease. HD is a devastating disease that places an intolerable burden on those who suffer from the disorder and their families. The inherited nature of the disease means that family members who act as carers may be doing so with the absolute knowledge that they themselves are going to develop the disease later in life. There are currently no disease-modifying treatments for HD. Significant breakthroughs in our understanding of the pathogenesis of the disease conveys hope to patients and families, and will encourage participation in clinical trials. Understanding the mechanistic underpinnings of the disease will assist in the development of treatments for the benefit of patients.

More widely, the discovery of underlying pathogenic processes and/or therapeutic targets in one neurodegenerative disorder offers hope for researchers working on and patients affected by many others. Neurodegenerative disease is having a serious and long-term impact on an aging UK population, with effects extending from the immeasurable burden on the lives of those affected, to the wider social and economic implications of long-term care. Studies estimate that neurodegenerative disease already costs the UK economy more than cancer and heart disease combined. Due to the likely irreversible nature of the neuronal loss during neurodegeneration, therapies need to target the pre-degenerative disease state. Research in HD, for which there is predictive genetic test that can establish with absolute certainty whether a person will develop the disease later in life, may form the basis of the development of preventative treatments in other neurodegenerative disorders.

Finally, this grant will provide Ralph Andre with the resources to capitalise on his work to date on neuroinflammation as a modifier of disease in HD. He has made a large contribution to the preparation of this grant application; this funding will allow him to build a highly competitive CV from which he can launch his independent career. It will benefit the field by ensuring that a highly capable young investigator is committed to work on HD for the foreseeable future.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1074952</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr Vincent Plagnol</gtr:description><gtr:id>6CB72805-9691-4449-A0AA-E70D73072CB2</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56d8168644ff27.08363277-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution and data analysis</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and data analyis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor Leslie Jones</gtr:description><gtr:id>3A177C8A-B7E2-4A6E-9F64-7965AB09B73C</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56d815be83a2c8.18833676-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor Peter Holmanns</gtr:description><gtr:id>ADFF736F-9B5E-4FC4-AA12-9239F0B116F7</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56d8160cbbf547.96159840-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Professor Gillian Bates</gtr:description><gtr:id>1C553995-D089-42FB-BDE1-1CC07B32DC9F</gtr:id><gtr:impact>Gill Bates - she has been collaborating with Gill Bates since 2000&amp;nbsp;and is co-applicant on another MRC grant with Gill Bates: 3 papers from 2006 are: Tsang T, Woodman B, McGloughlin G, Griffin J, Tabrizi SJ, Bates GP, Holmes E. Metabanomic Characterisation of the R6/2 Transgenic Mouse Model of Huntington's Disease by High-Resolution MAS 1H NMR spectroscopy. Journal of Proteome Research. 2006 Mar;5(3):483-92. Alexandra Zourlidou, Tali Gidalevitz , Mark Kristiansen , Ben Woodman, Dominic J. Wells, David S. Latchman, Jackie de Belleroche, S. J. Tabrizi, Richard I. Morimoto and Gillian P. Bates. Hsp27 overexpression in the R6/2 mouse model of Huntington's Disease: Chronic Neurodegeneration does not Induce Hsp27 Activation. Human Molecular Genetics. Epub 2007 Mar 14. 2007 May 1;16(9):1078-90. Annette Dalrymple, Edward J Wild, Richard Joubert, Kirupa Sathasivam, Maria Bj&amp;ouml;rkqvist, &amp;Aring;sa Peters&amp;eacute;n, Jeremy Isaacs, Mark Kristiansen, Gillian P Bates Blair R Leavitt, Geoff Keir, Malcolm Ward, S. J Tabrizi. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and candidate biomarkers Journal of Proteome Research. 2007 Jul;6(7):2833-40. 2008 -2011 Identification and Cross-validation of Early Stage Phenotypes in Mouse Models of Huntington's disease. Ref G0800846 - MRC - Models of Disease grant. Co-applicant with Professor Gillian Bates (PI) and Dr Michael Modeo (co-applicant). &amp;pound;910,736</gtr:impact><gtr:outcomeId>54958F5241D-1</gtr:outcomeId><gtr:partnerContribution>I was co-applicant on this grant. As well as funding there was intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual Contribution and Reagents. Running in vivo aspects of the project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Massachusetts (UMass)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Professor Neil Aronin</gtr:description><gtr:id>E3C03B4F-DB6F-44A7-B159-4598B20CB6A6</gtr:id><gtr:impact>Tr&amp;auml;ger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hummerich H, Antoniou M, Bates GP, Luthi-Carter R, Lowdell MW, Bj&amp;ouml;rkqvist M, Ostroff GR, Aronin N, Tabrizi SJ. HTT-lowering reverses Huntington's disease immune dysfunction caused by NF?B pathway dysregulation. Brain. 2014 Mar; 137 (Pt 3):819-33.</gtr:impact><gtr:outcomeId>56d580157a7733.51016019-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr Paul Lavender</gtr:description><gtr:id>3624C661-C0EB-4C9F-88DA-0B2506A64DBC</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56d81509f0b940.59352421-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor David Greaves</gtr:description><gtr:id>20B210BF-7EEC-4E4C-BE11-9944CD1D03AB</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56d8155d677bf2.08743530-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Evotec</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Andreas Weiss</gtr:description><gtr:id>64F90B40-3872-42B4-A6CD-2EAB1E5038F8</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56d81737233747.50412769-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presented poster at European Huntington's Disease Network 2016 Conference, The Hague</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B3AE12A9-B536-4C1C-ADC2-D00C7CE18284</gtr:id><gtr:impact>Presentation of a poster titled 'Innate transcriptional dysregulation is associated with proinflammatory pathway activation in Huntington's disease myeloid cells. Ralph Andre, James RC Miller, Kitty K Lo, Davina J Hensman Moss, Ulrike Tr&amp;auml;ger, Timothy C Stone, Peter McErlean, Lesley Jones, Peter Holmans, Paul Lavender, Vincent Plagnol and Sarah J Tabrizi
Generated questions from attendees and discussions about future plans</gtr:impact><gtr:outcomeId>58c7c82902e236.81219148</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Oxford University Departmental Seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2F783888-FF5B-49FF-9EAF-0D0E37D39BE0</gtr:id><gtr:impact>Presented talk entitled 'Meeting the Therapeutic Challenge in Huntington's disease'. Generated questions from audience and discussion</gtr:impact><gtr:outcomeId>58c7fda6b66400.90038405</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at European Huntington's Disease Network 2016 Conference, The Hague</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6C1EF745-3BDB-4CFB-8D44-9FF4254C6692</gtr:id><gtr:impact>Presented poster: 
Ralph Andre1, James RC Miller1, Kitty K Lo2, Davina J Hensman Moss1, Ulrike Tr&amp;auml;ger1#, Timothy C Stone3, Peter McErlean4, Lesley Jones3, Peter Holmans3, Paul Lavender4, Vincent Plagnol2 and Sarah J Tabrizi1. Innate transcriptional dysregulation is associated with proinflammatory pathway activation in Huntington's disease myeloid cells

Generated questions from attendees and discussions about future research plaans</gtr:impact><gtr:outcomeId>58c7c6a103ad76.84408047</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at 28th Cambridge Neuroscience Seminar, Cambridge University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4A0752DA-5909-49D3-8BEF-99AC9D1922A8</gtr:id><gtr:impact>Presented talk entitled 'Meeting the therapeutic challenge in Huntington's disease'</gtr:impact><gtr:outcomeId>58c8094b8be2d7.45791144</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk a Lancet Neurology Conference 2017, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9A1B3C2B-9EE3-4EA4-9C7D-46C5746629A6</gtr:id><gtr:impact>Presented talk entitled 'Gene silencing approaches for Huntington's disease'. Generated questions and audience discussions.

Prof Tabrizi also organised this meeting</gtr:impact><gtr:outcomeId>58c8033b5dbf76.75163728</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Association of British Neurologists Special Interest Group Meeting 2017, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C73A769E-226E-44DA-ABB6-47A61BB7062F</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Silencing abnormal proteins&amp;quot;. Generated discussion and questions from the audience</gtr:impact><gtr:outcomeId>58c7ff3f06a016.57801789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Huntington Study Group Conference and Satellite Symposium, Nashville</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C35F9377-E764-4BE3-B5D1-845F8E0D7AA3</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Neuroimaging endpoints for HD studies and Track-HD data&amp;quot;. Talk generated questions and audience discussion</gtr:impact><gtr:outcomeId>58c80151bbb265.17785294</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Hereditary Disease Foundation, The Milton Wexler Celebration of Life Symposium 2017, Massachusetts</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C2DD8EA6-39AC-4483-ACE6-9B3C2FFD514D</gtr:id><gtr:impact>Presented talk entitled 'Early Clinical Development of IONIS-HTTR'. Talk generated questions and audience discussion</gtr:impact><gtr:outcomeId>58c806cdc54114.53725010</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at European Huntington's Disease Network 2016 Conference, The Hague</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>63AA989A-BC56-46F6-B927-5FDC3CCFEBC7</gtr:id><gtr:impact>Presented poster titled: 'Abnormal bioenergetics in inclusion-containing mutant HTT exon 1 primary human neurons. Alison Wood-Kaczmar, Rhia Ghosh, Janos Kriston-Vizi, Edward Smith, Wayne Chadwick, Iain Hargreaves, Simon Heales, Andrey Abramov, Sarah Cole, Robin Ketteler, Gillian Bates, Ralph Andre, Sarah J Tabrizi.
Poster generated questions from attendees and discussions about future research plans.</gtr:impact><gtr:outcomeId>58c7c7eae64d13.25553683</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at &quot;20th International Congress of Parkinson's Disease and Movement Disorders, Berlin&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D6D7B882-5CCB-4F56-9D2B-1B460CFF85B4</gtr:id><gtr:impact>Presented talk entitled 'Complex phenotypes and genotypes - seeing the wood for the trees, presentation titled Huntington's disease and HD-like disorders'. Generated audience discussion and questions</gtr:impact><gtr:outcomeId>58c80831888fe0.80592347</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Imperial College Neuroscience Society's Conference 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C67D559A-2CEC-4E8E-86D5-90F1A289E173</gtr:id><gtr:impact>Presented talk titled 'Meeting the therapeutic challenge in Huntington's disease'. Generated questions and audience discussion</gtr:impact><gtr:outcomeId>58c7fe99c43ee2.32615895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at 11th Warsaw International Medical Congress for Young Scientists, Medical University of Warsaw</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E6B006D1-4228-42F0-9157-73480D160852</gtr:id><gtr:impact>Presented talk entitled ''Meeting the therapeutic challenge in Huntington's disease'. Generated questions and discussion with audience</gtr:impact><gtr:outcomeId>58c808e03c7270.99088465</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presneted talk at CASMI / UCLH BRC / UCL Personalised Medicine Domain Symposium 2017, London, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D04F4F4A-F4A6-4235-B5C7-4CA3DB20EFA9</gtr:id><gtr:impact>Presented talk entitled 'Cellular and gene therapies'. Generated questions and discussion with audience</gtr:impact><gtr:outcomeId>58c7fd2a10e280.81733135</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at Hereditary Disease Foundation Conference 2016, Boston</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>136FA13A-8AC0-43A8-A4F1-BA6DDDC2BD28</gtr:id><gtr:impact>Presented poster entitled 'Abnormal bioenergetics in inclusion containing mutant HTT exon 1 primary human neurons'. Generated questions from attendees.</gtr:impact><gtr:outcomeId>58c7c63449ac76.64263687</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brains Talk Seminar at Roche</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B16BAC24-3AA0-40D0-8FD6-F182ADF96AB3</gtr:id><gtr:impact>Presented seminar on Hutington's Disease to Roche Pharmaceuticals to aid company strategic planning</gtr:impact><gtr:outcomeId>56d872c7e2e880.66674310</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Present talk at European Huntington's Disease Network Conference 2016, The Hague</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BCD02534-9DBE-4B18-A5BA-0BEA8FB8CD67</gtr:id><gtr:impact>Presented talk entitled 'Gene targeting therapies for Huntington's disease'. Generated talk questions and audience discussion</gtr:impact><gtr:outcomeId>58c803c713ff93.14891112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Division of Brain Sciences, Imperial College London, Charing Cross Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6A8F16AB-AC0E-40C1-B802-C7BCEECA775E</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Meeting the Therapeutic Challenge in Huntington's disease&amp;quot;. Talk generated questions and audience participation</gtr:impact><gtr:outcomeId>58c801dc014d12.31934554</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Teaching to UCL MSc students</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7BDE7588-0156-44F5-941F-5073DA030584</gtr:id><gtr:impact>Teaching to UCL post-graduate students</gtr:impact><gtr:outcomeId>56d5810289ea73.60708832</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at UCL SLMS 2016 Clinical Academic Trainees Symposium, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>51DADBF4-DD0A-4031-B394-67B282312A45</gtr:id><gtr:impact>Presented talk entitled 'Gene silencing approaches for Huntington's disease'. Talk generated questions and audience discussions.</gtr:impact><gtr:outcomeId>58c8074bcf1058.35176601</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HD Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>24997B38-6114-41F8-B738-7F8D89F454FA</gtr:id><gtr:impact>Articles of this nature serve to enhance engagement with my research

Positive feedback from patients and healthcare professionals</gtr:impact><gtr:outcomeId>F69F56AC87A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented poster at European Huntington's Disease Network 2016 Conference, The Hague</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>013B26ED-4A40-4267-A021-6AA187F5C02F</gtr:id><gtr:impact>Preseented poster titled 'ASSESSMENT OF IMMUNE SYSTEM ACTIVATION STATUS DURING THE COURSE OF HUNTINGTON'S DISEASE IN HD MOUSE MODELS. Jeffrey Pido-Lopez, Ralph Andre, Agnesska Benjamin, Sophie A. Franklin, Sarah J. Tabrizi and Gillian P. Bates'
Poster generated questions and discussions about future research plans</gtr:impact><gtr:outcomeId>58c7c72b6ba2a0.14191312</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Primary human monocyte RNAseq from HD patients. RNAseq performed by deCODE, available within the NeurOmics consortium.</gtr:description><gtr:id>CFACFE92-C01E-4477-A318-FE29FAEA984F</gtr:id><gtr:impact>Published in Human Molecular Genetics</gtr:impact><gtr:outcomeId>58c7ca2c16f560.05214545</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RNA sequencing</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>01449071-CB0E-48B9-9422-2C7FAF002DAF</gtr:id><gtr:title>Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b221fed6781009f7f2986ae6a9ddddbb"><gtr:id>b221fed6781009f7f2986ae6a9ddddbb</gtr:id><gtr:otherNames>Miller JRC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa68cc137d470.49120752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFBC93A0-0205-4CF7-B214-700D46D877EC</gtr:id><gtr:title>Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a30e37c21a81f7625f8924ecdce9bed9"><gtr:id>a30e37c21a81f7625f8924ecdce9bed9</gtr:id><gtr:otherNames>Tr?ger U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>544e5c315a4430.18638492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C160D74-499E-4EB6-997C-4A924611468B</gtr:id><gtr:title>RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c91c19e9fd174710fd50739e4f6ada4"><gtr:id>7c91c19e9fd174710fd50739e4f6ada4</gtr:id><gtr:otherNames>Miller JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>58c276964b7dc5.38868487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>844CF405-BAFE-4A2B-A7AB-49BFC803B353</gtr:id><gtr:title>HTT-lowering reverses Huntington's disease immune dysfunction caused by NF?B pathway dysregulation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a30e37c21a81f7625f8924ecdce9bed9"><gtr:id>a30e37c21a81f7625f8924ecdce9bed9</gtr:id><gtr:otherNames>Tr?ger U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544f7871ddda10.59227905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3195986-A647-4B11-A614-3939D1BDE543</gtr:id><gtr:title>Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c91c19e9fd174710fd50739e4f6ada4"><gtr:id>7c91c19e9fd174710fd50739e4f6ada4</gtr:id><gtr:otherNames>Miller JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d85caf4c1627.17128011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E61AB512-17F9-4DB1-9877-6F405F3BADA5</gtr:id><gtr:title>Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e025e0770ab6775f7402cc2ed94e2155"><gtr:id>e025e0770ab6775f7402cc2ed94e2155</gtr:id><gtr:otherNames>Dobson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>56d85cb0b188e1.47217273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16FF2B6C-4F4C-4A2E-9DFE-C9FBF804DB2A</gtr:id><gtr:title>A Computational Cognitive Biomarker for Early-Stage Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ffa6dc59b5c7f6eb866504163d6059"><gtr:id>77ffa6dc59b5c7f6eb866504163d6059</gtr:id><gtr:otherNames>Wiecki TV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d85cb0dd7ef3.13472003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C66C7CF4-925D-4849-B618-C3F9EA6440E4</gtr:id><gtr:title>DNA repair in the trinucleotide repeat disorders.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ac40b969c64db850e438e12bb3e323"><gtr:id>59ac40b969c64db850e438e12bb3e323</gtr:id><gtr:otherNames>Jones L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>58c2758625fb27.63341062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AD229C7-DDEB-428A-86BB-283FBBF113DB</gtr:id><gtr:title>Biomarker development for Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>544f7aa2dca725.46294548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C29476F2-DBDF-4A2E-80A7-CCC4FB1E7DE7</gtr:id><gtr:title>DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>58a4cf8c235a65.74510136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1480A54-AB21-4126-8A7A-E5D02E57E219</gtr:id><gtr:title>Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>56d85cafaff572.05960906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EB9DF10-563E-4A00-BBFC-56853EB2A47B</gtr:id><gtr:title>Huntington disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Disease primers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a6d340b1c9dd22889424ee21a45141"><gtr:id>46a6d340b1c9dd22889424ee21a45141</gtr:id><gtr:otherNames>Bates GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2056-676X</gtr:issn><gtr:outcomeId>56d85cad8d91d2.89562883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0B8E563-38E5-4AFD-B703-1D1735043A97</gtr:id><gtr:title>Structural imaging in premanifest and manifest Huntington disease.</gtr:title><gtr:parentPublicationTitle>Handbook of clinical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/611f202ad90c9900b8baf6c0f7a04781"><gtr:id>611f202ad90c9900b8baf6c0f7a04781</gtr:id><gtr:otherNames>Scahill RI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0072-9752</gtr:issn><gtr:outcomeId>5aa68560c14038.54439021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D017989-0A4B-4B15-BADC-74D2D3101C88</gtr:id><gtr:title>Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd80e09e39e33140492c6a9c2603025"><gtr:id>cfd80e09e39e33140492c6a9c2603025</gtr:id><gtr:otherNames>Rodrigues FB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c27697b8a457.43872254</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L02053X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>